Improving Outcomes for Patients with Allergic Rhinitis and Asthma: An Interactive Clinical Case Challenge
Release date: June 2009
Expiration date: June30, 2010
Estimated time to complete activity: 0.75 hours
Program Overview
A clinical case will be utilized, covering a range of topics including allergy, asthma, and associated comorbidities. This case will be presented and discussed by an expert panel in a highly interactive manner. Video presentation of the case will be interspersed with evidence-based slides illustrating the latest data supporting clinical decision-making.
Target Audience
This activity has been designed to meet the educational needs of practicing allergists/immunologists, fellows in accredited allergy/immunology training programs, and primary care physicians who care for allergy patients.
Learning Objectives
Upon completion of this educational activity, participants should be better able to:
- Describe the role of small airway inflammation in patients with asthma
- Apply the National Asthma Education and Prevention Program’s Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3) treatment guidelines with regard to assessing asthma severity and control in clinical practice
Credit Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Accreditation Statement
The ACAAI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The ACAAI takes responsibility for the content, quality, and scientific integrity of this CME activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The ACAAI, Integrity Continuing Education, Inc. and Sepracor Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the ACAAI, Integrity Continuing Education, Inc. or Sepracor Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure of Conflicts of Interest
Each faculty member has been requested to complete a faculty disclosure statement. If the reader would like to see the actual signed disclosure forms, please contact the ACAAI at 847-427-1200.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lawrence M. DuBuske, MD
Consultant: Abbott, Allergy Therapeutics, AstraZeneca, Genentech, GlaxoSmithKline, Inspire, Merck & Co., Novartis, sanofi-aventis, Schering-Plough, Sepracor, UCB
Honorarium: Alcon, Allergy Therapeutics, AstraZeneca, Genentech, GlaxoSmithKline, Merck & Co., Novartis, sanofi-aventis, Schering-Plough, Sepracor, UCB
Research Grant: Alcon, Allergy Therapeutics, Genentech, Novartis, sanofi-aventis, Schering-Plough, UCB
Speaker’s Bureau: Allergy Therapeutics, AstraZeneca, Genentech, GlaxoSmithKline, Merck & Co., Novartis, sanofi-aventis, Schering-Plough, Sepracor, UCB
Eli O. Meltzer, MD
Consultant: Abbott, Adelphi, Alcon, Allux, Amgen, AstraZeneca, CAPNIA, Critical Therapeutics, DEY, Evolutec, Genentech, GlaxoSmithKline, Greer, Inspire, KOS, MedPointe, Merck & Co., Novartis, Pfizer, Rigel, sanofi-aventis, Schering-Plough, Shionogi, VentiRx, Verus, Wyeth
Research Grant: Alcon, Allux, Apotex, AstraZeneca, Boehringer Ingelheim, CAPNIA, Clay-Park, Critical Therapeutics, Genentech, GlaxoSmithKline, Hoffmann-LaRoche, KOS, Map Pharmaceuticals, Medicinova, MedPointe, Merck & Co., Naryx, Novartis, Pharmaxis, Rigel, sanofi-aventis, Schering-Plough, SkyePharma, TEVA, VOCEL, Wyeth
Speaker's Bureau: Alcon, AstraZeneca, Genentech, GlaxoSmithKline, MedPointe, Merck & Co., Pfizer, sanofi-aventis, Schering-Plough, Verus
David P. Skoner, MD
Consultant: Merck & Co., Schering-Plough
Research Grant: Alcon, AstraZeneca, GlaxoSmithKline, Greer Laboratories, Merck & Co., Novartis, sanofi-aventis, Schering-Plough
Speaker’s Bureau: AstraZeneca, GlaxoSmithKline, Merck & Co., Novartis, sanofi-aventis, Schering-Plough
Myron J. Zitt, MD
Consultant: Alcon, AstraZeneca, Genentech, Merck & Co., Novartis, sanofi-aventis, Schering-Plough, Sepracor, TEVA
Honorarium: Alcon, AstraZeneca, Genentech, Merck & Co., Novartis, sanofi-aventis, Schering-Plough, Sepracor, TEVA
Speaker’s Bureau: Alcon, AstraZeneca, Genentech, Merck & Co., Novartis, sanofi-aventis, Schering-Plough, Sepracor, TEVA
Directions to the Learner
There are no fees for participating and receiving CME credit for this activity. During the period of June 2009 through June 30, 2010, participants must:
- Read the learning objectives and faculty disclosures
- Study the educational activity
- Complete the posttest by recording the best answer to each question in the answer key on the evaluation form
- Complete the posttest and evaluation form
Disclaimer
The primary purpose of the ACAAI Annual Meeting and this material is education. Information, as well as technologies, products, and/or services discussed, are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exist in the specialty and the views of the ACAAI disclaims any and all liability for damages to any individual participating in this activity for all claims which may result from the use of information, technologies, products, and/or services discussed.
CONTINUE |
